Trial Profile
Drug Use Investigation for XYZAL
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Levocetirizine (Primary)
- Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jun 2013 Planned End Date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 05 Oct 2011 New trial record